Stock Taper
SCREENER COMPARE ANY 2 STOCKS
NAMS
NEWAMSTERDAM PHARMA COMPANY N.V.
NASDAQ
$25.90
▼ DOWN 3.32% (-0.89)

KEY STATISTICS

Market Cap$3.03 B
52w High$42.20
52w Low$23.05
Dividend Yield—
Frequency—
P/E-11.99
Volume1.04M
Shares Out.116.90M

COMPANY

LEADERSHIP

Michael Harvey Davidson Facp.
CHIEF EXECUTIVE
Michael Harvey Davidson Facp.

COMPENSATION 2026

Salary$621,300
Stock Awards$0
Incentive Plan Pay$497,040
All Other Comp.$3,897
Total$6,469,297

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 9, 2021
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
100

PRICE TARGET

Target High$58.00
Target Low$45.00
Target Median$51.00
Target Consensus$51.33

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$7.54M
NOV
4
WED

PRICE

$25.90 ▼ DOWN 3.32% (−$0.89)
$25.60$26.00$26.40$26.809:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM25.90

About NewAmsterdam Pharma Company N.V.

https://www.newamsterdampharma.com ↗

NewAmsterdam Pharma, founded in 2019 in the Netherlands, is a clinical-stage biopharmaceutical company developing obicetrapib, a CETP inhibitor aimed at improving lipid profiles and patient care in metabolic diseases.

INDUSTRY

Biotechnology

A PRODUCT NEWAMSTERDAM PHARMA COMPANY N.V. IS KNOWN FOR

Obicetrapib
Obicetrapib

Obicetrapib is a late-stage, oral CETP inhibitor designed to lower LDL-C and reduce cardiovascular risk, targeting patients who do not respond well to or cannot tolerate existing therapies.

COMPETITORS

COMPETITOR
AMGN COMPARE
ARWR COMPARE
BBIO COMPARE
ES ESPR COMPARE
VKTX COMPARE

Revenue by Products

IconPRODUCTQ2-2023
License Revenue$4.56M

ETFS HOLDING THIS STOCK

ETFS HOLDING
43
LISTED HERE
15
RANKED BY POSITION SIZE
CGMM
0.50% · 705.2K
IBB
0.15% · 599.5K
VHT
0.02% · 183.1K
SBIO
1.55% · 144.2K
FFSM
0.11% · 41.4K
GURU
1.22% · 29.7K
DRKY
2.99% · 21.4K
BBC
0.53% · 10.3K
ZPRS.DE
0.01% · 9.9K
IBBQ
0.20% · 7.3K
STXK
0.08% · 2.8K
XGEN.L
0.29% · 1.3K
TNXT
0.12% · 857
USUE.DE
0.00% · 308
GTPE
0.00% · 59

INSTITUTIONAL OWNERSHIP

SHARES OWNED
83.08%
HOLDERS
245
TOP 12 OF 245 · RANKED BY POSITION SIZE
Frazier Life Sciences Management, L.P.
18.1M sh · $613.03M
Capital World Investors
12.2M sh · $414.49M
Bain Capital Life Sciences Investors, LLC
10.7M sh · $304.85M
Fmr LLC
10.3M sh · $350.41M
Ra Capital Management, L.P.
10.1M sh · $288.35M
Fcpm Iii Services B.V.
9.2M sh · $262M
Viking Global Investors LP
6.5M sh · $184.16M
Wellington Management Group Llp
5.1M sh · $163.76M
Deerfield Management Company, L.P. (Series C)
4.3M sh · $121.34M
Jennison Associates LLC
4.2M sh · $119.41M
Maverick Capital Ltd
3.3M sh · $110.75M
Duquesne Family Office LLC
3.1M sh · $104.05M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity5
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: CHIEF SCIENTIFIC OFFICER
Kastelein Johannes Jacob Pieter
Sale · 125.0K shares
2026-08-24
★
DIRECTOR, OFFICER: CHIEF SCIENTIFIC OFFICER
Kastelein Johannes Jacob Pieter
Purchase · 125.0K shares
2026-08-24
★
Gunning Robert William
— · —
2026-08-10
★
OFFICER: CHIEF ACCOUNTING OFFICER
Kooij Louise Frederika
Sale · 80.0K shares
2026-07-20

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OUTPERFORM 1
NEUTRAL 1
6 GRADES IN THE LAST 12 MONTHS
RBC Capital OUTPERFORM Guggenheim BUY Needham BUY Stifel BUY Goldman Sachs NEUTRAL Citigroup BUY

SECTORS PEERS

PEERPRICE
KYMR$118.15COMPARE
PRAX$344.75COMPARE
CRNX$84.84COMPARE
IMVT$41.20COMPARE
CGON$74.34COMPARE
LGND$280.49COMPARE
VKTX$32.16COMPARE